Information Provided By: 
Fly News Breaks for January 25, 2018
BIIB, KPTI
Jan 25, 2018 | 11:20 EDT
H.C. Wainwright analyst Edward White believes the KPT-350 sale bodes well for Karyopharm Therapeutics (KPTI) since Biogen (BIIB), as a leader in neuroscience, is better suited for the advancement of the drug. After speaking to Karyopharm management, the analyst believes the company's focus remains in executing the development of oral selinexor in oncology. White keeps a Buy rating on the shares with a $23 price target.
News For KPTI;BIIB From the Last 2 Days
